BIIB vs. MRNA: A Head-to-Head Stock Comparison

Updated on November 19, 2025

Here’s a clear look at BIIB and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	BIIB	MRNA
Company Name	Biogen Inc.	Moderna, Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	24.51 billion USD	9.70 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	September 17, 1991	December 7, 2018
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of BIIB and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BIIB vs. MRNA: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	BIIB	MRNA
5-Day Price Return	7.23%	0.04%
13-Week Price Return	20.89%	-11.60%
26-Week Price Return	36.04%	-2.82%
52-Week Price Return	1.06%	-41.22%
Month-to-Date Return	8.61%	-8.80%
Year-to-Date Return	9.57%	-40.43%
10-Day Avg. Volume	1.95M	11.56M
3-Month Avg. Volume	1.62M	10.45M
3-Month Volatility	33.63%	59.86%
Beta	0.10	1.20

Profitability

Return on Equity (TTM)

BIIB

9.26%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

BIIB’s Return on Equity of 9.26% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.

MRNA

-31.40%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

MRNA has a negative Return on Equity of -31.40%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

BIIB vs. MRNA: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

BIIB

15.99%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

BIIB’s Net Profit Margin of 15.99% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

MRNA

-139.61%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

MRNA has a negative Net Profit Margin of -139.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

BIIB vs. MRNA: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

BIIB

21.91%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

An Operating Profit Margin of 21.91% places BIIB in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

MRNA

-155.15%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

MRNA has a negative Operating Profit Margin of -155.15%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

BIIB vs. MRNA: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	BIIB	MRNA
Return on Equity (TTM)	9.26%	-31.40%
Return on Assets (TTM)	5.67%	-24.44%
Net Profit Margin (TTM)	15.99%	-139.61%
Operating Profit Margin (TTM)	21.91%	-155.15%
Gross Profit Margin (TTM)	75.24%	63.49%

Financial Strength

Current Ratio (MRQ)

BIIB

2.72

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

BIIB’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

MRNA

3.93

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

BIIB vs. MRNA: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

BIIB

0.35

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

BIIB’s Debt-to-Equity Ratio of 0.35 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MRNA

0.01

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BIIB vs. MRNA: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

BIIB

4.35

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

MRNA

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

Interest Coverage Ratio data for MRNA is currently unavailable.

BIIB vs. MRNA: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	BIIB	MRNA
Current Ratio (MRQ)	2.72	3.93
Quick Ratio (MRQ)	2.05	3.40
Debt-to-Equity Ratio (MRQ)	0.35	0.01
Interest Coverage Ratio (TTM)	4.35	--

Growth

Revenue Growth

BIIB vs. MRNA: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BIIB vs. MRNA: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BIIB

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BIIB vs. MRNA: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

BIIB

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BIIB vs. MRNA: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	BIIB	MRNA
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

BIIB

15.20

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 15.20 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

MRNA

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

P/E Ratio data for MRNA is currently unavailable.

BIIB vs. MRNA: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

BIIB

2.43

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.43 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

MRNA

4.30

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 4.30 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

BIIB vs. MRNA: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

BIIB

1.13

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

BIIB’s P/B Ratio of 1.13 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

MRNA

1.08

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

MRNA’s P/B Ratio of 1.08 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

BIIB vs. MRNA: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	BIIB	MRNA
Price-to-Earnings Ratio (TTM)	15.20	--
Price-to-Sales Ratio (TTM)	2.43	4.30
Price-to-Book Ratio (MRQ)	1.13	1.08
Price-to-Free Cash Flow Ratio (TTM)	10.81	31.69